KLOW-80

KLOW-80 is a multi-peptide research blend combining four well-characterized peptide fragments: BPC-157 10 mg, TB-500 10 mg, KPV 10 mg, and GHK 50 mg per vial. The combination is investigated in preclinical models for its potential to influence tissue-repair cascades, inflammatory signaling pathways, and skin/soft-tissue remodeling under controlled experimental conditions.

Per vial composition: BPC-157 10 mg • TB-500 10 mg • KPV 10 mg • GHK 50 mg

BPC-157: A gastric-derived pentadecapeptide studied for effects on angiogenic signaling, fibroblast migration, and cellular repair pathways within tendon, ligament, and GI models.
TB-500 (Thymosin β4 Fragment): Investigated for its interaction with actin dynamics, cell motility, and cytoskeletal organization in soft-tissue and cardiac models.
KPV: A tripeptide fragment of α-MSH explored for its influence on melanocortin-linked anti-inflammatory signaling, including modulation of select cytokine and chemokine readouts.
GHK: A tripeptide cofactor studied in dermal and extracellular-matrix frameworks for its role in collagen-related gene expression, ECM turnover, and skin-appearance parameters in research settings.

Soft-tissue and tendon-repair models • Joint and musculoskeletal frameworks • Inflammatory-cascade and cytokine/chemokine assays • Dermal and extracellular-matrix remodeling studies • Angiogenesis and wound-closure paradigms • Combined PK/PD profiling of multi-peptide blends • In vitro receptor/signaling investigations for BPC-157, TB-500, KPV, and GHK individually and in combination.

Revitalized Health research peptides are produced under cGMP-aligned conditions with pharmaceutical-grade inputs. Each KLOW-80 lot is blended to a fixed ratio of BPC-157 10 mg, TB-500 10 mg, KPV 10 mg, and GHK 50 mg per vial and confirmed at ≥99% purity by HPLC, with component identity verified via LC-MS/MS. Lots undergo appearance/solubility checks and microbial/endotoxin screening to research-grade specifications. Batch-specific Certificates of Analysis provide full analytical methods and results for traceability.

Store lyophilized KLOW-80 vials at 2–8 °C, protected from light and moisture. After reconstitution with bacteriostatic water, maintain at 2–8 °C and utilize within 20 days. Avoid repeated freeze–thaw cycles to preserve peptide-structure integrity and blend consistency for experimental use.

For laboratory research use only. Not intended for human consumption, therapeutic, or diagnostic application. Supplied exclusively to qualified professionals conducting controlled scientific investigations.

Identity: KLOW-80, a 4-peptide research blend containing:
• BPC-157 – 10mg
• TB-500 (Thymosin Beta-4 fragment) – 10mg
• KPV – 10mg (Lys-Pro-Val melanocortin tripeptide)
• GHK-Cu – 50mg (Copper-binding regeneration peptide)

Mode: BPC-157 is evaluated for angiogenesis, fibroblast migration, nitric-oxide modulation, and tissue protection under stress models. TB-500 is studied for actin-binding regulation, cell migration, vessel formation, and accelerated soft-tissue repair. KPV demonstrates MC1R-linked anti-inflammatory pathways, reducing NF-κB activity and cytokine output in epithelial and immune-cell models. GHK-Cu supports collagen remodeling, ECM repair, fibroblast activation, and antioxidant gene profiles.

Analytics: HPLC purity; LC-MS/MS identity; endotoxin testing via LAL; appearance/solubility verification. PD readouts: angiogenesis assays, fibroblast migration, inflammatory cytokine panels, MC1R signaling assays, collagen/elastin expression studies. Monitoring (research): local tolerance, inflammation markers, oxidative-stress markers, wound-healing progression models.